Spire Healthcare Group (LON:SPI) Receives “Buy” Rating from Berenberg Bank

Berenberg Bank reaffirmed their buy rating on shares of Spire Healthcare Group (LON:SPI) in a research note issued to investors on Tuesday morning, Marketbeat.com reports. They currently have a GBX 300 ($3.96) price target on the stock.

Spire Healthcare Group Stock Performance

Shares of SPI opened at GBX 234 ($3.09) on Tuesday. The company has a quick ratio of 0.74, a current ratio of 0.70 and a debt-to-equity ratio of 169.51. Spire Healthcare Group has a 52-week low of GBX 207 ($2.73) and a 52-week high of GBX 270.50 ($3.57). The company has a 50-day simple moving average of GBX 248.66 and a 200-day simple moving average of GBX 245.19. The company has a market capitalization of £944.94 million, a PE ratio of 3,342.86, a P/E/G ratio of 1.06 and a beta of 0.97.

Insider Transactions at Spire Healthcare Group

In other news, insider Justin Ash bought 21,100 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were bought at an average cost of GBX 236 ($3.12) per share, for a total transaction of £49,796 ($65,780.71). Corporate insiders own 34.71% of the company’s stock.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.